134 related articles for article (PubMed ID: 16316482)
1. Prevention of relapse in generalized anxiety disorder by escitalopram treatment.
Allgulander C; Florea I; Huusom AK
Int J Neuropsychopharmacol; 2006 Oct; 9(5):495-505. PubMed ID: 16316482
[TBL] [Abstract][Full Text] [Related]
2. Randomized placebo-controlled trial of escitalopram and venlafaxine XR in the treatment of generalized anxiety disorder.
Bose A; Korotzer A; Gommoll C; Li D
Depress Anxiety; 2008; 25(10):854-61. PubMed ID: 18050245
[TBL] [Abstract][Full Text] [Related]
3. [Efficacy and tolerability of escitalopram in anxiety disorders: a review].
Pelissolo A
Encephale; 2008 Sep; 34(4):400-8. PubMed ID: 18922243
[TBL] [Abstract][Full Text] [Related]
4. Relapse prevention and residual symptoms: a closer analysis of placebo-controlled continuation studies with escitalopram in major depressive disorder, generalized anxiety disorder, social anxiety disorder, and obsessive-compulsive disorder.
Bech P; Lönn SL; Overø KF
J Clin Psychiatry; 2010 Feb; 71(2):121-9. PubMed ID: 19961809
[TBL] [Abstract][Full Text] [Related]
5. A 24-week randomized, double-blind, placebo-controlled study of escitalopram for the prevention of generalized social anxiety disorder.
Montgomery SA; Nil R; Dürr-Pal N; Loft H; Boulenger JP
J Clin Psychiatry; 2005 Oct; 66(10):1270-8. PubMed ID: 16259540
[TBL] [Abstract][Full Text] [Related]
6. Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study.
Davidson JR; Bose A; Korotzer A; Zheng H
Depress Anxiety; 2004; 19(4):234-40. PubMed ID: 15274172
[TBL] [Abstract][Full Text] [Related]
7. Prevention of post-stroke generalized anxiety disorder, using escitalopram or problem-solving therapy.
Mikami K; Jorge RE; Moser DJ; Arndt S; Jang M; Solodkin A; Small SL; Fonzetti P; Hegel MT; Robinson RG
J Neuropsychiatry Clin Neurosci; 2014; 26(4):323-8. PubMed ID: 24457590
[TBL] [Abstract][Full Text] [Related]
8. Combining escitalopram with gaboxadol provides no additional benefit in the treatment of patients with severe major depressive disorder.
Kasper S; Ebert B; Larsen K; Tonnoir B
Int J Neuropsychopharmacol; 2012 Jul; 15(6):715-25. PubMed ID: 22008735
[TBL] [Abstract][Full Text] [Related]
9. Escitalopram prevents relapse in older patients with major depressive disorder.
Gorwood P; Weiller E; Lemming O; Katona C
Am J Geriatr Psychiatry; 2007 Jul; 15(7):581-93. PubMed ID: 17586783
[TBL] [Abstract][Full Text] [Related]
10. Health-related quality of life (HRQOL) among patients with Generalised Anxiety Disorder: evaluation conducted alongside an escitalopram relapse prevention trial.
Allgulander C; Jørgensen T; Wade A; François C; Despiegel N; Auquier P; Toumi M
Curr Med Res Opin; 2007 Oct; 23(10):2543-9. PubMed ID: 17825130
[TBL] [Abstract][Full Text] [Related]
11. Clinical efficacy of escitalopram combined with botulinum toxin A in patients with generalized anxiety disorder and comorbid headache.
Wang Y; Yang X; Ji X; Liu M; Zhou C
Psychopharmacology (Berl); 2023 Oct; 240(10):2061-2070. PubMed ID: 37481677
[TBL] [Abstract][Full Text] [Related]
12. A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients.
Boulenger JP; Huusom AK; Florea I; Baekdal T; Sarchiapone M
Curr Med Res Opin; 2006 Jul; 22(7):1331-41. PubMed ID: 16834832
[TBL] [Abstract][Full Text] [Related]
13. The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies.
Griebel G; Beeské S; Stahl SM
J Clin Psychiatry; 2012 Nov; 73(11):1403-11. PubMed ID: 23146246
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of escitalopram in patients with severe depression: a pooled analysis.
Llorca PM; Azorin JM; Despiegel N; Verpillat P
Int J Clin Pract; 2005 Mar; 59(3):268-75. PubMed ID: 15857321
[TBL] [Abstract][Full Text] [Related]
15. Impact of escitalopram treatment on Quality of Life Enjoyment and Satisfaction Questionnaire scores in major depressive disorder and generalized anxiety disorder.
Demyttenaere K; Andersen HF; Reines EH
Int Clin Psychopharmacol; 2008 Sep; 23(5):276-86. PubMed ID: 18703937
[TBL] [Abstract][Full Text] [Related]
16. A pilot controlled trial of bupropion XL versus escitalopram in generalized anxiety disorder.
Bystritsky A; Kerwin L; Feusner JD; Vapnik T
Psychopharmacol Bull; 2008; 41(1):46-51. PubMed ID: 18362870
[TBL] [Abstract][Full Text] [Related]
17. Duloxetine treatment for relapse prevention in adults with generalized anxiety disorder: a double-blind placebo-controlled trial.
Davidson JR; Wittchen HU; Llorca PM; Erickson J; Detke M; Ball SG; Russell JM
Eur Neuropsychopharmacol; 2008 Sep; 18(9):673-81. PubMed ID: 18559291
[TBL] [Abstract][Full Text] [Related]
18. Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder.
Pigott TA; Prakash A; Arnold LM; Aaronson ST; Mallinckrodt CH; Wohlreich MM
Curr Med Res Opin; 2007 Jun; 23(6):1303-18. PubMed ID: 17559729
[TBL] [Abstract][Full Text] [Related]
19. Escitalopram therapy for major depression and anxiety disorders.
Baldwin DS; Reines EH; Guiton C; Weiller E
Ann Pharmacother; 2007 Oct; 41(10):1583-92. PubMed ID: 17848424
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
Yevtushenko VY; Belous AI; Yevtushenko YG; Gusinin SE; Buzik OJ; Agibalova TV
Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
